JP2025170244A5 - - Google Patents

Info

Publication number
JP2025170244A5
JP2025170244A5 JP2025123800A JP2025123800A JP2025170244A5 JP 2025170244 A5 JP2025170244 A5 JP 2025170244A5 JP 2025123800 A JP2025123800 A JP 2025123800A JP 2025123800 A JP2025123800 A JP 2025123800A JP 2025170244 A5 JP2025170244 A5 JP 2025170244A5
Authority
JP
Japan
Prior art keywords
cancer
group
alkyl
agents
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025123800A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025170244A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/038586 external-priority patent/WO2020257549A2/en
Application filed filed Critical
Publication of JP2025170244A publication Critical patent/JP2025170244A/ja
Publication of JP2025170244A5 publication Critical patent/JP2025170244A5/ja
Pending legal-status Critical Current

Links

JP2025123800A 2019-06-20 2025-07-24 Pd-l1疾患の治療のための化合物 Pending JP2025170244A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962864002P 2019-06-20 2019-06-20
US62/864,002 2019-06-20
PCT/US2020/038586 WO2020257549A2 (en) 2019-06-20 2020-06-19 Compounds for treatment of pd-l1 diseases
JP2021574927A JP7818404B2 (ja) 2019-06-20 2020-06-19 Pd-l1疾患の治療のための化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021574927A Division JP7818404B2 (ja) 2019-06-20 2020-06-19 Pd-l1疾患の治療のための化合物

Publications (2)

Publication Number Publication Date
JP2025170244A JP2025170244A (ja) 2025-11-18
JP2025170244A5 true JP2025170244A5 (OSRAM) 2026-02-18

Family

ID=74040685

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021574927A Active JP7818404B2 (ja) 2019-06-20 2020-06-19 Pd-l1疾患の治療のための化合物
JP2025123800A Pending JP2025170244A (ja) 2019-06-20 2025-07-24 Pd-l1疾患の治療のための化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021574927A Active JP7818404B2 (ja) 2019-06-20 2020-06-19 Pd-l1疾患の治療のための化合物

Country Status (13)

Country Link
US (1) US11485708B2 (OSRAM)
EP (1) EP3986392A4 (OSRAM)
JP (2) JP7818404B2 (OSRAM)
KR (1) KR102841588B1 (OSRAM)
CN (1) CN114072135A (OSRAM)
AU (1) AU2020294781B2 (OSRAM)
BR (1) BR112021023750A2 (OSRAM)
CA (1) CA3139242A1 (OSRAM)
IL (1) IL288523A (OSRAM)
MA (1) MA55325A (OSRAM)
MX (1) MX2021015708A (OSRAM)
SG (1) SG11202112875UA (OSRAM)
WO (1) WO2020257549A2 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2849181T3 (es) 2009-04-22 2021-08-16 Viacyte Inc Composiciones celulares derivadas de células reprogramadas desdiferenciadas
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
US11266643B2 (en) 2019-05-15 2022-03-08 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
US11872217B2 (en) 2019-07-10 2024-01-16 Chemocentryx, Inc. Indanes as PD-L1 inhibitors
CR20220216A (es) 2019-10-16 2023-01-09 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
US11713307B2 (en) 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
KR20230030056A (ko) 2020-05-22 2023-03-03 알리고스 테라퓨틱스 인코포레이티드 Pd-l1을 표적화하기 위한 방법 및 조성물
US20240010642A1 (en) * 2021-01-05 2024-01-11 Southern Research Institute Modulators of programmed death-ligand-1
TWI770866B (zh) * 2021-03-10 2022-07-11 國立清華大學 鹵化物材料及包含該鹵化物材料之光學單元和光電元件
MX2023015503A (es) * 2021-07-02 2024-02-21 Ascletis Bioscience Co Ltd Compuestos heterociclicos como inmunomoduladores de las interacciones de pd-l1.
CA3240346A1 (en) 2021-12-16 2023-06-22 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
CN115010658B (zh) * 2022-05-11 2023-06-27 南方医科大学 一种化合物及其制备方法与应用
CN118265699A (zh) * 2022-10-26 2024-06-28 西安新通药物研究股份有限公司 一种非对称性联苯衍生物及其制备方法与医药用途
AU2023383986A1 (en) * 2022-11-22 2025-03-13 Xi'an Xintong Pharmaceutical Research Co., Ltd. Novel bicyclic pd-l1 inhibitors, preparation methods therefor and medicinal uses thereof
CN116903489B (zh) * 2023-07-14 2025-09-02 北京汉典制药有限公司 三联苯类化合物、其制备方法及其应用
KR102841053B1 (ko) * 2023-08-01 2025-08-04 (주)아이랩 Pd-l1 억제제로서 신규한 바이페닐 유도체

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2402317B1 (en) 2006-03-31 2013-07-03 Novartis AG DGAT inhibitor
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
ES2642074T3 (es) 2013-09-04 2017-11-15 Bristol-Myers Squibb Company Compuestos útiles como inmunomoduladores
CN105814028B (zh) 2013-09-06 2018-02-16 奥瑞基尼探索技术有限公司 作为免疫调节剂的1,2,4‑*二唑衍生物
EP3385257A1 (en) 2013-09-06 2018-10-10 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
JP6767096B2 (ja) * 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
MY199705A (en) 2015-12-22 2023-11-20 Incyte Corp Heterocyclic compounds as immunomodulators
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
RU2735541C2 (ru) 2016-05-23 2020-11-03 Инститьют Оф Материя Медика, Чайниз Экедеми Оф Медикал Сайенсез Простое эфирное производное никотинилового спирта, получение и фармацевтическая композиция и применения
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
KR102685249B1 (ko) 2016-06-20 2024-07-17 인사이트 코포레이션 면역조절제로서의 복소환식 화합물
KR102401963B1 (ko) 2016-06-27 2022-05-25 케모센트릭스, 인크. 면역조절제 화합물
WO2018005591A1 (en) * 2016-06-29 2018-01-04 Universite De Montreal Biarylmethyl heterocycles
EP3483142B1 (en) * 2016-07-05 2025-10-15 Beijing Maxinovel Pharmaceuticals Co., Ltd. Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
KR102491992B1 (ko) 2016-07-08 2023-01-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제로서 유용한 1,3-디히드록시-페닐 유도체
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018045142A1 (en) 2016-09-02 2018-03-08 Polaris Pharmaceuticals, Inc. Immune checkpoint inhibitors, compositions and methods thereof
JP7106572B2 (ja) 2016-12-20 2022-07-26 ブリストル-マイヤーズ スクイブ カンパニー 免疫調節剤として有用な化合物
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
CA3047991A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
US20180177784A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
PE20191532A1 (es) 2016-12-22 2019-10-23 Incyte Corp Compuestos heterociclicos como inmunomoduladores
WO2018119224A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
EP3564237A4 (en) 2016-12-29 2020-06-10 Shenzhen Chipscreen Biosciences Co., Ltd. UREA COMPOUND AND PRODUCTION METHOD AND USE THEREOF
CN108395443B (zh) 2017-02-04 2021-05-04 广州丹康医药生物有限公司 抑制程序性死亡受体配体1的环状化合物及其用途
JP7150745B2 (ja) 2017-03-27 2022-10-11 ブリストル-マイヤーズ スクイブ カンパニー 免疫調節剤としての置換イソキノリン誘導体
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TW201841896A (zh) 2017-04-26 2018-12-01 大陸商南京聖和藥業股份有限公司 作為pd—l1抑制劑的雜環類化合物
CN108863963B (zh) 2017-05-08 2022-05-27 南京圣和药物研发有限公司 作为pd-l1抑制剂的杂环类化合物
CN109400522B (zh) 2017-08-18 2023-04-28 上海轶诺药业有限公司 一种具有pd-l1抑制活性的化合物、其制备方法及用途
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators
CN109665968B (zh) 2017-10-16 2022-02-22 四川科伦博泰生物医药股份有限公司 并环化合物及其制备方法和用途
CN109678796B (zh) 2017-10-19 2023-01-10 上海长森药业有限公司 Pd-1/pd-l1小分子抑制剂及其制备方法和用途
CN109721527B (zh) 2017-10-27 2024-03-12 广州丹康医药生物有限公司 一种新型抗pd-l1化合物、其应用及含其的组合物
BR112020008851A2 (pt) 2017-11-06 2020-10-20 Jubilant Prodel LLC composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
WO2019120297A1 (zh) 2017-12-22 2019-06-27 上海海雁医药科技有限公司 免疫调节剂及其制法与医药上的用途
EP3733659B1 (en) 2017-12-29 2023-12-20 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
JP7214752B2 (ja) 2018-01-23 2023-01-30 ブリストル-マイヤーズ スクイブ カンパニー 免疫調節剤として有用な2,8-ジアシル-2,8-ジアザスピロ[5.5]ウンデカン化合物
ES3035608T3 (en) 2018-02-05 2025-09-05 Abbisko Therapeutics Co Ltd Biaryl derivatives and their pharmaceutical application for the treatment of pd-1/pd-l1 signal pathway-mediated diseases
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2019169123A1 (en) 2018-03-01 2019-09-06 Bristol-Myers Squibb Company Compounds useful as immunomodulators
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
WO2019174533A1 (zh) 2018-03-13 2019-09-19 广东东阳光药业有限公司 Pd-1/pd-l1类小分子抑制剂及其在药物中的应用
RS64055B1 (sr) 2018-03-30 2023-04-28 Incyte Corp Heterociklična jedinjenja kao imunomodulatori
CN111936475B (zh) 2018-04-03 2024-05-10 贝达药业股份有限公司 免疫调节剂及其组合物和制备方法
EP4600247A3 (en) * 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
MD3790877T2 (ro) 2018-05-11 2023-08-31 Incyte Corp Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1
WO2020011209A1 (zh) 2018-07-11 2020-01-16 上海和誉生物医药科技有限公司 免疫抑制剂及其制备方法和在药学上的应用
CN112384500B (zh) 2018-07-12 2024-05-14 贝达药业股份有限公司 免疫调节剂及其组合物和制备方法
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
US20210269440A1 (en) 2018-07-19 2021-09-02 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
CN112424194B (zh) 2018-07-19 2024-02-06 贝达药业股份有限公司 免疫调节剂及其组合物和制备方法
US20210347785A1 (en) 2018-08-01 2021-11-11 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Preparation and application of aromatic compound having immunoregulatory function
CN109336857A (zh) 2018-11-13 2019-02-15 南方医科大学 一种含取代联苯的黄酮及其应用
CN109438263A (zh) 2018-11-28 2019-03-08 南方医科大学 一种含取代联苯的萘及其应用
CN109503546A (zh) 2019-01-10 2019-03-22 南方医科大学 一种间苯二酚二苯甲醚及其应用
CN109776377B (zh) 2019-02-01 2021-08-24 沈阳药科大学 吲哚啉类化合物及其制备方法和应用
CN109776445B (zh) 2019-03-28 2022-12-06 中国药科大学 苯并噁二唑类化合物及其制备方法和医药用途
US11266643B2 (en) * 2019-05-15 2022-03-08 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
CN110200959A (zh) 2019-05-30 2019-09-06 天津科技大学 一种黄酮类化合物的应用
CN110128415B (zh) 2019-05-31 2022-03-25 沈阳药科大学 用作免疫调节剂的吲哚啉类化合物及其制备方法

Similar Documents

Publication Publication Date Title
JP2022531970A5 (OSRAM)
JP2022536845A5 (OSRAM)
JP2022551973A5 (OSRAM)
JP2022551972A5 (OSRAM)
JP2019527202A5 (OSRAM)
JP2011510995A5 (OSRAM)
JP2018158926A5 (OSRAM)
JP2020528905A5 (OSRAM)
JP2009513703A5 (OSRAM)
JP5746172B2 (ja) ホスホイノシチド3−キナーゼ阻害剤としての三環式複素環化合物
JP2023512038A5 (OSRAM)
KR101258426B1 (ko) 세포 증식과 관련된 질환 치료용 배합물
JP2022551668A5 (OSRAM)
JP2023515235A5 (OSRAM)
JP2016510783A5 (OSRAM)
JP2004514718A5 (OSRAM)
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
CN111194214A (zh) 施用sting激动剂的方法
RU2014153800A (ru) Соединения 5-азаиндазола и способы их применения
RU2014131378A (ru) Ингибиторы бромдомена
CN109568312A (zh) 用于治疗癌症的化合物
AU2010243213B2 (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
RU2017139515A (ru) Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там
JP2020504716A5 (OSRAM)
JP2018529739A5 (OSRAM)